Scientific Reports (Sep 2024)

Elevated body mass index is not significantly associated with reduced influenza vaccine effectiveness

  • Jennifer P. King,
  • Huong Q. Nguyen,
  • Erika L. Kiniry,
  • C. Hallie Phillips,
  • Manjusha Gaglani,
  • Emily T. Martin,
  • Krissy Moehling Geffel,
  • Mary Patricia Nowalk,
  • Jessie R. Chung,
  • Brendan Flannery,
  • Edward A. Belongia

DOI
https://doi.org/10.1038/s41598-024-72081-z
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Elevated body mass index (BMI) has been linked to severe influenza illness and impaired vaccine immunogenicity, but the relationship between BMI and clinical vaccine effectiveness (VE) is less well described. This secondary analysis of data from a test-negative study of outpatients with acute respiratory illness assessed BMI and VE against medically attended, PCR-confirmed influenza over seven seasons (2011–12 through 2017–18). Vaccination status was determined from electronic medical records (EMR) and self-report; BMI was estimated from EMR-documented height and weight categorized for adults as obesity (≥ 30 kg/m2), overweight (25–29 kg/m2), or normal and for children based on standardized z-scales. Current season VE by virus type/subtype was estimated separately for adults and children. Pooled VE for all seasons was calculated as 1—adjusted odds ratios from logistic regression with an interaction term for BMI and vaccination. Among 28,089 adults and 12,380 children, BMI category was not significantly associated with VE against outpatient influenza for any type/subtype. Adjusted VE against A/H3N2, A/H1N1pdm09, and B in adults ranged from 16–31, 46–54, and 44–57%, and in children from 29–34, 57–65, and 50–55%, respectively, across the BMI categories. Elevated BMI was not associated with reduced VE against laboratory confirmed, outpatient influenza illness.

Keywords